Browse Category

NASDAQ:PRLD News 4 November 2025

Prelude Therapeutics (PRLD) Stock’s Wild Ride: 150% Surge, Big Pharma Deal & What’s Next

Prelude Therapeutics (PRLD) Stock’s Wild Ride: 150% Surge, Big Pharma Deal & What’s Next

A Wild Week for PRLD Stock Prelude Therapeutics – a small precision oncology biotech – suddenly became one of the market’s most volatile stocks in early November 2025. On Monday, Nov 3, PRLD shares skyrocketed, at one point gaining over 150%. The stock surged from roughly $1.60 into the $3–4 range, fueled by speculative buzz and unusually heavy tradingrttnews.com. More than 29 million shares changed hands in a single day (versus an average of ~250,000), and the price hit a 52-week high of $4.19rttnews.com. By the session’s end, Prelude closed near $4 – an astronomical one-day move for a company

Stock Market Today

REA Group share price slides after $200m buyback plan — what ASX investors watch next

REA Group share price slides after $200m buyback plan — what ASX investors watch next

8 February 2026
REA Group shares fell 7.8% to A$168.10 after its half-year update showed a 6% rise in EBITDA and a 9% gain in core net profit, but a 24% drop in reported net profit. The company flagged softer listing volumes and announced a A$200 million buyback starting Feb. 23. Interim dividend is A$1.24 per share, ex-dividend March 3. Investors cited pressure from weaker listings and rising costs.
NAB share price in focus after Friday slide as rate rises and bank updates loom

NAB share price in focus after Friday slide as rate rises and bank updates loom

8 February 2026
National Australia Bank shares closed down 1.6% at A$43.36 on Friday after the S&P/ASX 200 fell nearly 2%, its worst session in almost a year. NAB, CBA, and Westpac will raise variable mortgage rates by 0.25% following the Reserve Bank’s hike to 3.85%. Key sector results are due from CBA on Feb. 11, Westpac on Feb. 13, and NAB on Feb. 18.
Go toTop